This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

Correction: Oncolytic and Gene Therapy Using HYPR-Ad-IL4

View larger version (125K): [in this window] [in a new window] [Download PPT slide]   Figure 4. Histology and immunohistochemistry of HYPR-Ad-mIL4–treated tumors. LN229 tumors were intratumorally treated with PBS (A), HYPR-Ad-mIL4 (B),or dl309-Ad (C) as described in the legend of Fig. 3. Fifteen days from the start of treatment, animals were injected with pimonidazole hydrochloride (a 2-nitroimidazolehypoxia marker) and sacrificed, and the tumors were harvested. Deparaffinized tumor sections were stained with H&E for tumor histology and detection of infiltratingPMN leukocytes and with Masson's trichrome to detect collagen (blue). Immunostaining was done for Ad hexon protein, pimonidazole (hypoxia) adduct, andCD45 leukocyte common antigen, a pan-lymphocyte marker. Magnifications: A, C, and D, 50x; B, 100x; and E, 400x. Representative sections are shown.

1. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, Tighiouart M, Van Meir EG. Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007;67:6872–81.[Abstract/Free Full Text]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content